Progress in Animal and Clinical Studies on the Impact of Bisphosphonates on Implant Stability

Linglu JIA; Zikai GONG; Wenxi ZHAO; Yong WEN

doi:10.3881/j.issn.1000-503X.16365

PDF(846 KB)

Acta Academiae Medicinae Sinicae ›› 2025, Vol. 47 ›› Issue (4) : 628-633. DOI: 10.3881/j.issn.1000-503X.16365

Review Articles

Progress in Animal and Clinical Studies on the Impact of Bisphosphonates on Implant Stability

Linglu JIA ¹^,²^,³^,⁴ ,
Zikai GONG ²^,³^,⁴^,⁵ ,
Wenxi ZHAO ²^,³^,⁴^,⁵ ,
Yong WEN ²^,³^,⁴^,⁵

Author information +

History +

Abstract

Bisphosphonates(BP),a class of commonly used medications for treating osteoporosis and bone malignancies,significantly affect bone metabolism.When dental implants are placed in patients receiving BP,the potential impacts of BP on the formation and long-term maintenance of implant osseointegration cannot be ignored.In addition,the influence of dental implants on the occurrence of BP-related osteonecrosis of the jaw is garnering attention.This article explores the influences of BP on the stability of dental implants based on a review of previous animal and clinical studies,discusses the impact of dental implants on the occurrence of BP-related osteonecrosis of the jaw,and proposes suggestions for the dental implant treatment of patients taking BP in clinical practice.This review is expected to provide a theoretical basis for the related research and clinical treatment.

Key words

bisphosphonates / implants / osseointegration / medication-related osteonecrosis of the jaw

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

Linglu JIA , Zikai GONG , Wenxi ZHAO , et al. Progress in Animal and Clinical Studies on the Impact of Bisphosphonates on Implant Stability[J]. Acta Academiae Medicinae Sinicae. 2025, 47(4): 628-633 https://doi.org/10.3881/j.issn.1000-503X.16365

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

[1]	Barbosa JS, Almeida Paz FA, Braga SS. Bisphosphonates,old friends of bones and new trends in clinics[J]. J Med Chem, 2021, 64(3):1260-1282.DOI:10.1021/acs.jmedchem.0c01292. Cited in this article [3]

[2]	Ebetino FH, Sun S, Cherian P, et al. Bisphosphonates:the role of chemistry in understanding their biological actions and structure-activity relationships,and new directions for their therapeutic use[J]. Bone, 2022, 156(1):116289.DOI:10.1016/j.bone.2021.116289. Cited in this article [1]

[3]	Srivichit B, Thonusin C, Chattipakorn N, et al. Impacts of bisphosphonates on the bone and its surrounding tissues:mechanistic insights into medication-related osteonecrosis of the jaw[J]. Arch Toxicol, 2022, 96(5):1227-1255.DOI:10.1007/s00204-021-03220-y. Cited in this article [5]

[4]	Ruggiero SL, Dodson TB, Aghaloo T, et al. American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update[J]. J Oral Maxillofac Surg, 2022, 80(5):920-943.DOI:10.1016/j.joms.2022.02.008. Cited in this article [10]

[5]	Altalhi AM, Alsubaihi AA, Aldosary MM, et al. Enhancing the oral rehabilitation and quality of life of bisphosphonate-treated patients:the role of dental implants[J]. Cureus, 2023, 15(10):e46654.DOI:10.7759/cureus.46654. Cited in this article [1]

[6]	Lee ES, Tsai MC, Lee JX, et al. Bisphosphonates and their connection to dental procedures:exploring bisphosphonate-related osteonecrosis of the jaws[J]. Cancers(Basel), 2023, 15(22):5366.DOI:10.3390/cancers15225366. Cited in this article [1]

[7]	Taniguchi N, Osaki M, Onuma K, et al. Bisphosphonate-induced reactive oxygen species inhibit proliferation and migration of oral fibroblasts:a pathogenesis of bisphosphonate-related osteonecrosis of the jaw[J]. J Periodontol, 2020, 91(7):947-955.DOI:10.1002/JPER.19-0385. Cited in this article [1]

[8]	Guirguis RH, Tan LP, Hicks RM, et al. In vitro cytotoxicity of antiresorptive and antiangiogenic compounds on oral tissues contributing to mronj:systematic review[J]. Biomolecules, 2023, 13(6):973.DOI:10.3390/biom13060973. Cited in this article [1]

[9]	Budzinska A, Galganski L, Jarmuszkiewicz W. The bisphosphonates alendronate and zoledronate induce adaptations of aerobic metabolism in permanent human endothelial cells[J]. Sci Rep, 2023, 13(1):16205.DOI:10.1038/s41598-023-43377-3. Cited in this article [1]

[10]	Gkouveris I, Soundia A, Gouveris P, et al. Macrophage involvement in medication-related osteonecrosis of the jaw(mronj):a comprehensive,short review[J]. Cancers(Basel), 2022, 14(2):330.DOI:10.3390/cancers14020330. Cited in this article [1]

[11]	Dikicier E, Karacayli U, Dikicier S, et al. Effect of systemic administered zoledronic acid on osseointegration of a titanium implant in ovariectomized rats[J]. J Craniomaxillofac Surg, 2014, 42(7):1106-1111.DOI:10.1016/j.jcms.2014.01.039. Cited in this article [2]

[12]	Li JP, Li P, Hu J, et al. Early healing of hydroxyapatite-coated implants in grafted bone of zoledronic acid-treated osteoporotic rabbits[J]. J Periodontol, 2014, 85(2):308-316.DOI:10.1902/jop.2013.130046. Cited in this article [2]

[13]	Verzola MH, Frizzera F, de Oliveira GJ, et al. Effects of the long-term administration of alendronate on the mechanical properties of the basal bone and on osseointegration[J]. Clin Oral Implants Res, 2015, 26(12):1466-1475.DOI:10.1111/clr.12492. Cited in this article [2]

[14]	Karlsson J, Martinelli A, Fathali HM, et al. The effect of alendronate on biomineralization at the bone/implant interface[J]. J Biomed Mater Res A, 2016, 104(3):620-629.DOI:10.1002/jbm.a.35602. Cited in this article [2]

[15]	Khojasteh A, Dehghan MM, Nazeman P. Immediate implant placement following 1-year treatment with oral versus intravenous bisphosphonates:a histomorphometric canine study on peri-implant bone[J]. Clin Oral Investig, 2019, 23(4):1803-1809.DOI:10.1007/s00784-018-2579-7. Cited in this article [6]

[16]	Oh KC, Hwang W, Park YB, et al. Effects of alendronate on bone remodeling around osseointegrated implants in rats[J]. Implant Dent, 2017, 26(1):46-53.DOI:10.1097/ID.0000000000000497. Cited in this article [2]

[17]	Chacon GE, Stine EA, Larsen PE, et al. Effect of alendronate on endosseous implant integration:an in vivo study in rabbits[J]. J Oral Maxillofac Surg, 2006, 64(7):1005-1009.DOI:10.1016/j.joms.2006.01.007. Cited in this article [1]

[18]	Pandey A, Verma S, Malhan S, et al. Evaluation of effect of bisphosphonates on dental implant therapy in postmenopausal women using cone beam computed tomography[J]. J Contemp Dent Pract, 2019, 20(1):51-55.DOI:10.5005/jp-journals-10024-2475. Cited in this article [1]

[19]	French D, Grandin HM, Ofec R. Retrospective cohort study of 4 591 dental implants:analysis of risk indicators for bone loss and prevalence of peri-implant mucositis and peri-implantitis[J]. J Periodontol, 2019, 90(7):691-700.DOI:10.1002/JPER.18-0236. Cited in this article [1]

[20]	Kim JY, Choi H, Park JH, et al. Effects of anti-resorptive drugs on implant survival and peri-implantitis in patients with existing osseointegrated dental implants:a retrospective cohort study[J]. Osteoporos Int, 2020, 31(9):1749-1758.DOI:10.1007/s00198-019-05257-3. Cited in this article [1]

[21]	Jung J, Ryu JI, Shim GJ, et al. Effect of agents affecting bone homeostasis on short-and long-term implant failure[J]. Clin Oral Implants Res, 2023, 34(Suppl 26):143-168.DOI:10.1111/clr.14144. Cited in this article [6]

[22]	Mendes V, Dos Santos GO, Calasans-Maia MD, et al. Impact of bisphosphonate therapy on dental implant outcomes:an overview of systematic review evidence[J]. Int J Oral Maxillofac Surg, 2019, 48(3):373-381.DOI:10.1016/j.ijom.2018.09.006. Cited in this article [1]

[23]	Gelazius R, Poskevicius L, Sakavicius D, et al. Dental implant placement in patients on bisphosphonate therapy:a systematic review[J]. J Oral Maxillofac Res, 2018, 9(3):e2.DOI:10.5037/jomr.2018.9302. Cited in this article [2]

[24]	Sulaiman N, Fadhul F, Chrcanovic BR. Bisphosphonates and dental implants:a systematic review and meta-analysis[J]. Materials(Basel), 2023, 16(18):6078.DOI:10.3390/ma16186078. Cited in this article [2]

[25]	Ting M, Huynh BH, Woldu HG, et al. Clinical impact on dental implant survival in patients taking antiresorptive medications:a systematic review and meta-analysis[J]. J Oral Implantol, 2023, 49(6):599-615.DOI:10.1563/aaid-joi-D-21-00160. Cited in this article [1]

[26]	Abtahi J, Henefalk G, Aspenberg P. Impact of a zoledronate coating on early post-surgical implant stability and marginal bone resorption in the maxilla-a split-mouth randomized clinical trial[J]. Clin Oral Implants Res, 2019, 30(1):49-58.DOI:10.1111/clr.13391. Cited in this article [1]

[27]	Zuffetti F, Testori T, Capelli M, et al. The topical administration of bisphosphonates in implant surgery:a randomized split-mouth prospective study with a follow-up up to 5 years[J]. Clin Implant Dent Relat Res, 2015, 17(Suppl 1):e168-e176.DOI:10.1111/cid.12151. Cited in this article [1]

[28]	Kc K, Bhattarai BP, Shrestha S, et al. Effect of locally delivered bisphosphonates on alveolar bone:a systematic review and meta-analysis[J]. J Evid Based Dent Pract, 2021, 21(3):101580.DOI:10.1016/j.jebdp.2021.101580. Cited in this article [1]

[29]	Park JH, Lee JR, Lee H, et al. No increased risk of osteonecrosis of the jaw in osteoporotic patients with dental implants:a nationwide cohort study[J]. Clin Oral Investig, 2024, 28(1):83.DOI:10.1007/s00784-023-05483-4. Cited in this article [4]

[30]	Pichardo SEC, van der Hee JG, Fiocco M, et al. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws(mronj)[J]. Br J Oral Maxillofac Surg, 2020, 58(7):771-776.DOI:10.1016/j.bjoms.2020.03.022. Cited in this article [2]

[31]	Tempesta A, Capodiferro S, Mauceri R, et al. Peri-implantitis-like medication-related osteonecrosis of the jaw:clinical considerations and histological evaluation with confocal laser scanning microscope[J]. Oral Dis, 2022, 28(6):1603-1609.DOI:10.1111/odi.13873. Cited in this article [3]

[32]	Kim JW, Landayan ME, Lee JY, et al. Role of microcracks in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw[J]. Clin Oral Investig, 2016, 20(8):2251-2258.DOI:10.1007/s00784-016-1718-2. Cited in this article [2]

[33]	Seki K, Namaki S, Kamimoto A, et al. Medication-related osteonecrosis of the jaw subsequent to peri-implantitis:a case report and literature review[J]. J Oral Implantol, 2021, 47(6):502-510.DOI:10.1563/aaid-joi-D-19-00385. Cited in this article [1]

[34]	Escobedo MF, Cobo JL, Junquera S, et al. Medication-related osteonecrosis of the jaw.Implant presence-triggered osteonecrosis:case series and literature review[J]. J Stomatol Oral Maxillofac Surg, 2020, 121(1):40-48.DOI:10.1016/j.jormas.2019.04.012. Cited in this article [2]

[35]	Watts NB, Grbic JT, Binkley N, et al. Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 years[J]. J Clin Endocrinol Metab, 2019, 104(6):2443-2452.DOI:10.1210/jc.2018-01965. Cited in this article [1]

[36]	Al-Omari FA, Kuroshima S, Sawase T. Medication-related osteonecrosis of the jaw induced by regenerative therapy in implant dentistry:a scoping review[J]. J Dent, 2023,138:104682.DOI:10.1016/j.jdent.2023.104682. Cited in this article [1]

[37]	Campisi G, Mauceri R, Bertoldo F, et al. Medication-related osteonecrosis of jaws(mronj)prevention and diagnosis:Italian consensus update 2020[J]. Int J Environ Res Public Health, 2020, 17(16):5998.DOI:10.3390/ijerph17165998. Cited in this article [3]

[38]	Bodem JP, Kargus S, Eckstein S, et al. Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction[J]. J Craniomaxillofac Surg, 2015, 43(4):510-514.DOI:10.1016/j.jcms.2015.02.018. Cited in this article [1]

[39]	Aljohani S, Gaudin R, Weiser J, et al. Osteonecrosis of the jaw in patients treated with denosumab:a multicenter case series[J]. J Craniomaxillofac Surg, 2018, 46(9):1515-1525.DOI:10.1016/j.jcms.2018.05.046. Cited in this article [1]

[40]	Jung SY, Suh HS, Park JW, et al. Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw[J]. Oral Dis, 2019, 25(2):471-480.DOI:10.1111/odi.12966. Cited in this article [1]

[41]	Ottesen C, Schiodt M, Gotfredsen K. Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw(mronj):a systematic review[J]. Heliyon, 2020, 6(4):e03795.DOI:10.1016/j.heliyon.2020.e03795. Cited in this article [1]